Alliance Pharma PLC Director Dealings (2931Q)
17 October 2023 - 4:13AM
UK Regulatory
TIDMAPH
RNS Number : 2931Q
Alliance Pharma PLC
16 October 2023
16 October 2023
ALLIANCE PHARMA PLC
("Alliance" or the " Company ")
Director Dealings
Alliance Pharma plc (AIM: APH), the international healthcare
group , has been notified that on 13(th) October 2023 each of Peter
Butterfield, Chief Executive Officer of Alliance, and Andrew
Franklin, Chief Financial Officer, have exercised share options
pursuant to the Company's Long Term Incentive Plan as set out
below.
Peter Butterfield has exercised options over 98,342 ordinary
shares of 1 pence each in the Company ("Ordinary Shares"). These
options were granted in 2019 at nil cost and were set to expire on
5 December 2023. Following this exercise, 74,343 Ordinary Shares
were sold at a price of GBP0.39016 per share, with an element of
the proceeds being applied to satisfy the nominal value exercise
price of the options, costs and tax liabilities. In accordance with
the Company's share retention policy, following this transaction,
Mr Butterfield has a beneficial interest in 466,103 Ordinary Shares
and 1,818,750 vested but unexercised share options.
Andrew Franklin has exercised options over 55,592 Ordinary
Shares. These options were granted in 2019 at nil cost and were set
to expire on 5 December 2023. Following this exercise, 42,053
Ordinary Shares were sold at a price of GBP0.39016 per share, with
an element of the proceeds being applied to satisfy the nominal
value exercise price of the options, costs and tax liabilities. In
accordance with the Company's share retention policy, following
this transaction, Mr Franklin has a beneficial interest in 192,911
Ordinary Shares and 1,450,501 vested but unexercised share
options.
The notification below, made in accordance with the requirements
of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them.
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name Peter Butterfield
------------------------------ -----------------------------------------------------
2 Reason for the notification
-------------------------------------------------------------------------------------
a) Position/status Chief Executive Officer
------------------------------ -----------------------------------------------------
b) Initial notification Initial Notification
/Amendment
------------------------------ -----------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------------------
a) Name ALLIANCE PHARMA PLC
------------------------------ -----------------------------------------------------
b) Legal Entity 213800RYIWZA4Q5WPZ13
Identifier
------------------------------ -----------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------------------------
a) Description of Ordinary shares of 1 pence each
the financial
instrument, type
of instrument GB0031030819
Identification
code
------------------------------ -----------------------------------------------------
b) Nature of the a) Exercise of options
transaction b) Sale of Ordinary Shares
------------------------------ -----------------------------------------------------
c) Currency GBP
------------------------------ -----------------------------------------------------
d) Price(s) and Price(s) Volume(s)
volume(s)
------------------------------ ------------------------------------ ---------------
a) 1 pence (nominal a) 98,342
value) b) 74,343
b) GBP0.39016
------------------------------ ------------------------------------ ---------------
e) Aggregated information a) 98,342 options over Ordinary Shares, at
- Aggregated nil cost save par value per share (being
volume 1 pence per share and an aggregate of GBP983.42).
- Price
- Aggregated b) 74,343 Ordinary Shares, sold at an average
total price of GBP0.39016 per Ordinary Share, totalling
GBP 29,005.66
------------------------------ -----------------------------------------------------
f) Date of the transaction(s) 13 October 2023
------------------------------ -----------------------------------------------------
g) Place of the London Stock Exchange, AIM
transaction
------------------------------ -----------------------------------------------------
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name A ndrew Franklin
------------------------------ ----------------------------------------------------
2 Reason for the notification
------------------------------------------------------------------------------------
a) Position/status Chief Financial Officer
------------------------------ ----------------------------------------------------
b) Initial notification Initial Notification
/Amendment
------------------------------ ----------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
------------------------------------------------------------------------------------
a) Name ALLIANCE PHARMA PLC
------------------------------ ----------------------------------------------------
b) Legal Entity 213800RYIWZA4Q5WPZ13
Identifier
------------------------------ ----------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
------------------------------------------------------------------------------------
a) Description of Ordinary shares of 1 pence each
the financial
instrument, type
of instrument GB0031030819
Identification
code
------------------------------ ----------------------------------------------------
b) Nature of the c) Exercise of options
transaction d) Sale of Ordinary Shares
------------------------------ ----------------------------------------------------
c) Currency GBP
------------------------------ ----------------------------------------------------
d) Price(s) and Price(s) Volume(s)
volume(s)
------------------------------ ----------------------------------- ---------------
c) 1 pence (nominal a) 55,592
value) b) 42,053
d) GBP0.39016
------------------------------ ----------------------------------- ---------------
e) Aggregated information a) 55,592 options over Ordinary Shares, at
- Aggregated nil cost save par value per share (being
volume 1 pence per share and an aggregate of GBP555.92)
- Price
- Aggregated b) 42,053 Ordinary Shares, sold at an average
total price of GBP0.39016 pence per Ordinary Share,
totalling GBP16,407.40
------------------------------ ----------------------------------------------------
f) Date of the transaction(s) 13 October 2023
------------------------------ ----------------------------------------------------
g) Place of the London Stock Exchange, AIM
transaction
------------------------------ ----------------------------------------------------
For further information:
Alliance Pharma plc + 44 (0)1249 466966
Head of Investor Relations: Cora McCallum + 44 (0)1249 705168
ir@allianceph.com
Buchanan + 44 (0)20 7466 5000
Mark Court / Sophie Wills / Hannah Ratcliff
alliancepharma@buchanan.uk.com
Numis Securities Limited (Nominated Adviser
and Joint Broker) + 44 (0)20 7260 1000
Freddie Barnfield / Duncan Monteith /
Sher Shah
Investec Bank plc (Joint Broker) + 44 (0)20 7597 5970
Patrick Robb / Maria Gomez de Olea
About Alliance
Alliance Pharma plc (AIM: APH) is a growing consumer healthcare
company . Our purpose is to empower people to make a positive
difference to their health and wellbeing by making our trusted and
proven brands available around the world.
We deliver organic growth through investing in our priority
brands and channels, in related innovation, and through selective
geographic expansion to increase the reach of our brands.
Periodically, we may look to enhance our organic growth through
selective, complementary acquisitions .
Headquartered in the UK, the Group employs around 285 people
based in locations across Europe, North America, and the Asia
Pacific region. By outsourcing our manufacturing and logistics we
remain asset-light and focused on maximising the value we can
bring, both to our stakeholders and to our brands. For more
information on Alliance, please visit our website :
www.alliancepharmaceuticals.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHMZMMGNVGGFZM
(END) Dow Jones Newswires
October 16, 2023 13:13 ET (17:13 GMT)
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Apr 2023 to Apr 2024
